Financial MilestonesMedincell may receive up to $1.9B in total potential development and commercial milestones from its collaboration with AbbVie, plus royalties on worldwide sales.
Market PotentialBoth UZEDY and mdc-TJK are highly differentiated LAI antipsychotic products, with the ability to establish dominant market share within a $5B annual sales niche for the U.S. alone.
Product DevelopmentThe jointly developed MedinCell / Teva product candidate could be the first long-acting olanzapine with a favorable safety profile, since other LAIs of olanzapine have been associated with a black box warning on their FDA-authorized labels for post-injection delirium/sedation syndrome (PDSS), which severely limits their use.